North America’s medical devices industry saw a drop of 30.23% in deal activity during January 2021, when compared with the last 12-month average, led by OptumInsight’s $13bn acquisition of Change Healthcare, according to GlobalData’s deals database.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
A total of 60 medical devices industry deals worth $22.38bn were announced for the region in January 2021, against the 12-month average of 86 deals.
Of all the deal types, venture financing saw most activity in January 2021 with 27 transactions, representing a 45% share for the region.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIn second place was M&A with 26 deals, followed by private equity deals with seven transactions, respectively capturing a 43.3% and 11.7% share of the overall deal activity for the month.
In terms of value of deals, M&A was the leading category in North America’s medical devices industry with $21.21bn, while venture financing and private equity deals totalled $936.83m and $233.21m, respectively.
North America medical devices industry deals in January 2021: Top deals
The top five medical devices deals accounted for 89.4% of the overall value during January 2021.
The combined value of the top five medical devices deals stood at $20.01bn, against the overall value of $22.38bn recorded for the month.
The top five medical devices industry deals of January 2021 tracked by GlobalData were:
1) OptumInsight’s $13bn acquisition of Change Healthcare
2) The $4.6bn acquisition deal with Cantel Medical by Steris
3) Boston Scientific’s $1.23bn acquisition of Preventice
4) The $635m acquisition of Capsule Technologies by Koninklijke Philips
5) Thermo Fisher Scientific’s acquisition of Mesa Biotech for $550m.
